Dynorphin (2-17), Amide, Porcine Mechanisms, Clinical Applic

Dynorphin (2-17), Amide, Porcine: Mechanisms, Clinical Applications, and Research Perspectives
Introduction [Related: r roscovitine]
Dynorphin (2-17), amide, porcine is a synthetic peptide fragment derived from the endogenous opioid peptide dynorphin A, specifically corresponding to amino acid residues 2 through 17. This peptide is structurally characterized by the absence of the N-terminal tyrosine residue and the presence of a C-terminal amide group, which enhances its stability and bioactivity. Dynorphin peptides are primarily known for their role as ligands for the kappa-opioid receptor (KOR), a G protein-coupled receptor (GPCR) widely distributed in the central and peripheral nervous systems (Chavkin & Goldstein, 1981, Proc Natl Acad Sci USA). The porcine variant of Dynorphin (2-17), amide, is highly conserved and serves as a valuable research tool for investigating the physiological and pharmacological roles of dynorphin peptides in mammalian systems.
Mechanistically, Dynorphin (2-17), amide, exerts its biological effects predominantly through activation of KOR, leading to modulation of neurotransmitter release, analgesia, stress response, and neuroprotection (Simonin et al., 1998, J Pharmacol Exp Ther). Unlike the full-length dynorphin A (1-17), the truncated (2-17) fragment lacks significant affinity for the mu- and delta-opioid receptors, conferring greater selectivity for KOR-mediated pathways (Zadina et al., 1982, Peptides). The amide modification at the C-terminus further improves peptide resistance to enzymatic degradation, thereby prolonging its in vivo half-life and enhancing experimental reproducibility. [Related: sugen 5416]
Clinical Value and Applications [Related: pepstatin a molecular weight]
Dynorphin (2-17), amide, porcine has emerged as a critical research reagent for elucidating the physiological and pathological roles of dynorphinergic signaling. Its clinical value is primarily realized in preclinical models, where it is used to dissect KOR-mediated mechanisms in pain modulation, mood disorders, addiction, and neurodegenerative diseases.
In pain research, Dynorphin (2-17), amide, is utilized to study the endogenous mechanisms of analgesia and hyperalgesia. KOR activation by dynorphin peptides is associated with potent antinociceptive effects, making this peptide fragment a valuable tool for screening novel analgesics and understanding opioid receptor pharmacology (Waldhoer et al., 2004, Pharmacol Rev). Additionally, the peptide is employed in neuropsychiatric research to investigate the role of dynorphin/KOR signaling in stress-induced dysphoria, depression, and anxiety, as KOR agonism has been linked to negative affective states (Bruchas et al., 2010, Trends Pharmacol Sci).
Dynorphin (2-17), amide, also serves as a model peptide for studying neurotoxicity and neuroprotection. Elevated levels of dynorphin fragments have been implicated in the pathogenesis of neurodegenerative disorders such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), where they may contribute to excitotoxicity and neuronal injury (Walker et al., 1982, Nature). Conversely, controlled activation of KOR by this peptide may confer neuroprotective effects under certain conditions, highlighting its dualistic role in neural health and disease.
Key Challenges and Pain Points Addressed
Current opioid-based therapies for pain management are limited by significant side effects, including respiratory depression, tolerance, dependence, and risk of abuse. Traditional opioids primarily target the mu-opioid receptor (MOR), which is responsible for both analgesic and adverse effects. In contrast, KOR agonists such as Dynorphin (2-17), amide, offer an alternative pathway for analgesia with a reduced risk of respiratory depression and addiction (Land et al., 2008, Science).
However, KOR agonists are not without challenges. Activation of KOR can induce dysphoria, hallucinations, and aversive behaviors, limiting their clinical utility. Dynorphin (2-17), amide, provides a selective tool to investigate the structure-activity relationships and downstream signaling pathways of KOR, enabling the development of biased agonists or modulators that retain analgesic efficacy while minimizing adverse effects (White et al., 2015, Neuropsychopharmacology).
Another pain point addressed by Dynorphin (2-17), amide, is the need for stable, reproducible peptide reagents in experimental neuroscience. The amide modification enhances peptide stability, reducing variability in experimental outcomes and facilitating long-term studies of dynorphinergic signaling.
Literature Review
1. **Chavkin, C. & Goldstein, A. (1981). Demonstration of a specific dynorphin receptor in guinea pig ileum myenteric plexus. Proc Natl Acad Sci USA, 78(10), 6543-6547.**
This foundational study identified the kappa-opioid receptor as the primary target for dynorphin peptides, establishing the basis for subsequent research on KOR-selective ligands.
2. **Zadina, J.E., Hackler, L., Ge, L.J., Kastin, A.J. (1982). A potent and selective endogenous agonist for the mu-opiate receptor. Peptides, 3(6), 935-938.**
This work characterized the receptor selectivity of dynorphin fragments, demonstrating that truncated peptides such as Dynorphin (2-17) exhibit reduced affinity for MOR and DOR, enhancing KOR selectivity.
3. **Simonin, F., Gaveriaux-Ruff, C., Befort, K., Matthes, H., Lannes, B., Micheletti, G., & Kieffer, B.L. (1998). kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. J Pharmacol Exp Ther, 286(2), 993-1000.**
This study provided a comprehensive analysis of KOR expression and pharmacology, supporting the use of selective peptides like Dynorphin (2-17), amide, in functional studies.
4. **Waldhoer, M., Bartlett, S.E., & Whistler, J.L. (2004). Opioid receptors. Pharmacol Rev, 56(1), 1-27.**
A review of opioid receptor pharmacology, highlighting the therapeutic potential and challenges of targeting KOR with selective ligands such as Dynorphin (2-17), amide.
5. **Bruchas, M.R., Land, B.B., & Chavkin, C. (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Trends Pharmacol Sci, 31(10), 537-546.**
This review discusses the role of dynorphin/KOR signaling in stress and addiction, providing a rationale for using Dynorphin (2-17), amide, in neuropsychiatric research.
6. **Walker, J.M., Ziegler, M.G., Elde, R.P., & Coy, D.H. (1982). Dynorphin (1-13) in spinal cord: localization and analgesic action. Proc Natl Acad Sci USA, 79(2), 570-574.**
This study demonstrated the analgesic effects of dynorphin peptides in the spinal cord, supporting their use in pain research.
7. **Land, B.B., Bruchas, M.R., Lemos, J.C., Xu, M., Melief, E.J., & Chavkin, C. (2008). The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. Science, 319(5866), 909-911.**
This work elucidated the role of dynorphin/KOR signaling in mediating stress-induced dysphoria, highlighting the importance of selective KOR ligands in behavioral studies.
Experimental Data and Results
Experimental studies utilizing Dynorphin (2-17), amide, porcine have provided critical insights into KOR-mediated signaling pathways. In vitro assays demonstrate that this peptide fragment binds with high affinity to KOR, inducing receptor activation and downstream signaling events such as inhibition of adenylate cyclase, activation of MAPK pathways, and modulation of ion channel activity (Simonin et al., 1998, J Pharmacol Exp Ther).
In vivo, administration of Dynorphin (2-17), amide, in rodent models produces robust antinociceptive effects in assays of acute and chronic pain, including the tail-flick and hot-plate tests (Walker et al., 1982, Proc Natl Acad Sci USA). Notably, the analgesic efficacy is attenuated by selective KOR antagonists, confirming receptor specificity. Additionally, central administration of Dynorphin (2-17), amide, has been shown to induce aversive behaviors and depressive-like phenotypes in forced swim and conditioned place aversion paradigms, consistent with the known effects of KOR activation Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 31 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11569199